FDA approves Bayer’s Bluetooth-enabled auto-injector for multiple sclerosisFDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
Oral pain meds overtake injectable therapies as preferred treatment for multiple sclerosisOral therapies are revolutionizing the treatment paradigm of multiple sclerosis (MS), offering enhanced dosing and patient compliance, according to new analysis. Frost & Sullivan’s A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market found that recent therapeutic advancements aim at improving the tolerability of existing products, specifically for interferon beta and glatiramer acetate. Developing anti-inflammatory medications has also been a key area of focus.
Low vitamin D levels can predict multiple sclerosis progressionFor patients in the early stages of multiple sclerosis (MS), low levels of vitamin D were found to strongly predict disease severity and hasten its progression, according to a study online January 20, 2014 in JAMA Neurology.